Fog Pharmaceuticals
PrivateLast Round
Private Placement
Jun 12, 2026
Est. Valuation
$2.3B
Total Funding Raised
$812M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Parabilis Medicines is a biopharmaceutical company that develops Helicon™ peptide therapeutics designed to target and neutralize historically undruggable intracellular cancer-causing proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Fog Pharmaceuticals Comparables
Compare Fog Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Relay Therapeutics | 78% | |
| PeptiDream Inc. | 76% | |
| Recursion Pharmaceuticals | 76% |
Fog Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jun 12, 2026 | ||||
| IPO | Jun 10, 2026 | ||||
| Series F | Jan 8, 2026 | ||||
| Series E | Mar 1, 2024 | ||||
| Series D | Nov 21, 2022 | ||||
Series C | Mar 1, 2021 |
Fog Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series F |
| Deerfield Management | Series C, Series A, Seed, Series B, Series D |
| Evercore ISI | IPO |
| Janus Henderson Group | Series F |
| Horizons Ventures | Series B |
| SymBiosis Capital Management | Series E |
| Boyu Capital | Seed, Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 12, 2026
$75M round with participation from Regeneron Pharmaceuticals.
- Jun 10, 2026
$771M IPO round led by Guggenheim Securities.
Fog Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Fog Pharmaceuticals's valuation, stock price, and market status.
Is Fog Pharmaceuticals a public or private company?
Fog Pharmaceuticals is a private company.
What is the current stock price of Fog Pharmaceuticals?
Fog Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Fog Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Fog Pharmaceuticals worth (valuation)?
Fog Pharmaceuticals's valuation is estimated at $2.3B based on funding round data.
Can I buy Fog Pharmaceuticals stock?
Fog Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Fog Pharmaceuticals's last funding round?
Fog Pharmaceuticals's most recent funding round was Private Placement on June 12, 2026.
Who are the main investors in Fog Pharmaceuticals?
Key investors in Fog Pharmaceuticals include Deerfield Management, Evercore ISI, Janus Henderson Group, RA Capital Management, Farallon Capital Management.
Will Fog Pharmaceuticals IPO soon?
No public IPO plans have been announced for Fog Pharmaceuticals.
How can I track Fog Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Fog Pharmaceuticals's shares on secondary markets.